# A Study of ASP8273 in Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor-Naïve Patients With Non-Small Cell Lung Cancer Harboring EGFR Mutations

> **NCT02500927** · PHASE2 · TERMINATED · sponsor: **Astellas Pharma Inc** · enrollment: 31 (actual)

## Conditions studied

- EGFR-TKI-naïve Patients With NSCLC Harboring EGFR Activating Mutations

## Interventions

- **DRUG:** ASP8273 Capsules
- **DRUG:** ASP8273 Capsules A

## Key facts

- **NCT ID:** NCT02500927
- **Lead sponsor:** Astellas Pharma Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-06-25
- **Primary completion:** 2017-06-09
- **Final completion:** 2017-06-09
- **Target enrollment:** 31 (ACTUAL)
- **Why stopped:** Following recommendation by SOLAR Study IDMC, Astellas closed enrollment in ASP8273 studies.
- **Last updated:** 2024-11-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02500927

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02500927, "A Study of ASP8273 in Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor-Naïve Patients With Non-Small Cell Lung Cancer Harboring EGFR Mutations". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT02500927. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*